PAVmed Reports Q2 2025 Financial Results and Developments

The latest update is out from PAVmed ( (PAVM) ).

In its second quarter of 2025, PAVmed Inc. reported significant business developments and financial results. Lucid Diagnostics processed 2,756 EsoGuard tests, generating $1.2 million in revenue, and secured a Medicare LCD meeting for September 4, 2025. Veris Health completed financing and is advancing its implantable monitor towards FDA clearance, with strategic partnerships in place to enhance its commercial deployment. PAVmed’s financial results showed a GAAP net loss of $13.3 million, with a strengthened balance sheet and cash reserves of $4.0 million as of June 30, 2025.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

Spark’s Take on PAVM Stock

According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.

PAVmed’s overall stock score reflects significant financial challenges, with persistent losses and high leverage weighing heavily. While technicals indicate a bearish trend, the company’s strategic initiatives and recent financing offer some positive outlook. Valuation appears low, suggesting potential for upside if financial stability can be achieved.

To see Spark’s full report on PAVM stock, click here.

More about PAVmed

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. It has subsidiaries such as Lucid Diagnostics Inc. and Veris Health Inc., focusing on esophageal disease diagnostics and implantable physiological monitoring, respectively.

Average Trading Volume: 192,318

Technical Sentiment Signal: Sell

Current Market Cap: $7.65M

See more insights into PAVM stock on TipRanks’ Stock Analysis page.